Non-Hodgkin’s lymphoma Non-Hodgkin’s lymphoma plays an important role in lymphoma, due to the fact that non-Hodgkin’s lymphoma accounts for 80-90% of lymphomas. There are two major families of non-Hodgkin’s lymphoma, B-cell and T-cell. there are numerous subtypes of the B-cell family, which have very different biological characteristics, prognosis and treatment. Small cell types are inert, such as borderline B-cell lymphoma, follicular lymphoma, and small lymphocytic lymphoma, and some patients can remain in a stable state for a long time. In contrast, the set cell lymphoma is between inert and aggressive, and the current intervention methods are mainly chemotherapy and targeted therapy, which can achieve good results. The medium-sized cell type is Burkitt’s lymphoma, mostly seen in children, which can be cured in some cases by using short, flat and fast treatments. The large cell type is represented by diffuse large B-cell lymphoma, which has the highest proportion of B-cell lymphoma. It is not an independent disease, and is divided into more than 20 subtypes due to the diversity of its biological characteristics, and is considered partially curable due to the combination of targeted therapy Meroval and chemotherapy, which has significantly improved its cure rate. Most of the T-cell family are refractory except for large mesenchymal cell lymphoma with ALK(+), and the common ones are NK/T-cell lymphoma, T-lymphoblast lymphoma, and angioimmunoblast lymphoma, etc. The rest are classified as peripheral T non-specific. targeted therapy for T-cell lymphoma has also led to an increase in its cure rate. On January 6, 2012, the Lymphoma Department of Shanxi University Hospital was established, and three patients with set cell lymphoma were admitted on the same day, and nearly 10 more patients with this disease came one after another later. After targeted and standardized chemotherapy, all of them had good results and formed a group of patients with condyloma lymphoma. One of them was diagnosed 10 days ago in Beijing with maternal cell type condylomatous lymphoma, and repeated treatments have not improved. When he came to the big hospital with high white blood cells, low platelets and general pain, the patient and his family were anxious and turned the medical staff around. Director Zhang calmly said to them, “Let us doctors anxious, you do not anxious.” After the individualized targeted therapy, the patient is like a new person and often communicates with the lymphoma group and is full of smiles and gratitude when she sees the doctor. She is a beautiful middle-aged woman who was diagnosed with diffuse large B-cell lymphoma and had used chemotherapy for many times in outside hospitals. She suddenly coughed up blood and had unbearable chest pain, and was diagnosed with diffuse large B-cell lymphoma combined with severe pneumonia infective shock when she came to the hospital in an emergency. Director Zhang led all medical and nursing staffs to struggle to save the patient, and the doctor in charge stayed home for several days and nights, using antimicrobial broad-coverage treatment. After the efforts, the patient was finally out of the dangerous period and is now in the recovery period. During the Health Friday event, a middle-aged man took out a banner to thank Director Zhang for saving his life. He turned out to be a T-lymphoblastic lymphoma patient who had been recovering for three years. A tearful middle-aged woman in the audience saw hope when her 17-year-old daughter was diagnosed with T-lymphoblastoma of the primary breast, with fever, a huge breast lump, rupture and pus flow. The conventional surgical management was to remove the affected breast and drainage. She eagerly brought her child to a large hospital to seek help from Director Zhang, who boldly treated her with small doses of chemotherapy plus antimicrobial agents in the face of such a dangerous condition, and then a miracle occurred. The doctor was very pleased to see her bright smile and her uplifted chest. We not only gave her health, but also left her a beauty and added a confidence. Director Zhang’s words: 1. Non-Hodgkin’s lymphoma is divided into B and T cell type, and the typing is complex with numerous subtypes. 2. New technologies such as stem cell transplantation, targeted therapy and gene therapy show a bright future for the treatment of non-Hodgkin’s lymphoma. 3. If doctors do not give up and patients do not give up, there will be miracles of curing non-Hodgkin’s lymphoma patients.